Medicine & pharma · Official intelligence
EMA recommends approval for Zybrivo (sintilimab) for NSCLC
On 12 November 2026, the EMA's CHMP adopted a positive opinion recommending marketing authorization for Zybrivo (sintilimab). The applicant Fortvita seeks approval for this medicine to treat non-squamous non-small cell lung cancer in adults. This expands immunotherapy options for this specific cancer subtype.
Original source
Read the source — ema.europa.eu ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.